Home LiteratureArticle Details
PMID: 12738730 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck.

Akervall J, Bockmühl U, Petersen I, Yang K, Carey TE, Kurnit DM

Abstract

Tumor-Node-Metastasis classification does not fully predict outcome of treatment and prognosis in patients with squamous cell carcinoma of the head and neck. Different biomarkers have been suggested to yield additional prognostic information, but no single marker has thus far been introduced in the clinic. The objective of the present study was to analyze the copy number of the frequently amplified oncogenes CCND1 and c-MYC in relation to the commonly deleted tumor suppressor gene cyclin-dependent kinase (CDK)N2A (p16) to enhance the clinical significance. Extracted DNA from diagnostic biopsies of 78 untreated patients were analyzed by real-time PCR with specific primers for c-MYC, CCND1, and CDKN2A. Gene copy number ratios were calculated by dividing the copy number of c-MYC or CCND1 with CDKN2A. Ratios > 2 were defined as enhanced. These data were related to disease-free interval and disease-specific survival. Enhanced gene ratio of c-MYC:CDKN2A was detected in 35 of 78 (45%) and enhanced ratio of CCND1:CDKN2A in 36 of 78 (46%) of the cases. The c-MYC:CDKN2A and CCND1:CDKN2A ratios correlated with disease-specific survival with respect to death (P = 0.042 and 0.049, respectively; Log-rank test). Furthermore, enhancement of c-MYC:CDKN2A was associated with a shorter disease-free interval as marked by the development of recurrences or metastases (P = 0.014; Log-rank test). We conclude that CCND1 and/or c-MYC amplification, when combined with CDKN2A deletion, yield additional prognostic information as compared with analysis of single genetic aberrations. These gene ratios, as analyzed by a sensitive method like real-time PCR on diagnostic biopsies, might help clinicians to individualize the treatment of squamous cell carcinoma of the head and neck as they reflect the biological properties of the tumors. This could be used as an adjunct to the Tumor-Node-Metastasis classification system.

MeSH Terms
Carcinoma, Squamous Cell/genetics,pathology,secondary Cyclin D1/genetics Female Gene Amplification Gene Deletion Gene Dosage Genes, myc/genetics Genes, p16 Head and Neck Neoplasms/genetics,pathology Humans Male Neoplasm Recurrence, Local/genetics,pathology Neoplasm Staging Prognosis Survival Rate
Chemicals
Cyclin D1
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Akervall Jan
Department of Otolaryngology, Head and Neck Surgery, University of Michigan, Ann Arbor 48109, USA. jan.akervall@skane.se
Bockmühl Ulrike
Petersen I
Yang Kun
Carey Thomas E
Kurnit David M
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1078-0432
Published
2003-05-00
Pages
1750-5
Language
English
Region
United States
NLM ID
9502500
Subset
IM
Grants
NCI NIH HHS · 1 P50 CA97248 · United States
NIDCR NIH HHS · 1 R01 DE13346 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com